Biocryst Pharmaceuticals INC (BCRX) Holding Held by Dafna Capital Management Llc

March 14, 2018 - By Marie Mckinney

Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.01, from 1.68 in 2017Q2. It is positive, as 12 investors sold BCRX shares while 24 reduced holdings. 28 funds opened positions while 33 raised stakes. 79.80 million shares or 20.47% more from 66.24 million shares in 2017Q2 were reported. Ra Mngmt Lc holds 3.31% or 6.98M shares in its portfolio. Pacad Invest Ltd has 22,200 shares for 0.03% of their portfolio. Susquehanna Interest Gp Llp reported 38,923 shares. Artal Grp holds 650,000 shares. Alyeska Inv Grp Incorporated LP invested in 0.02% or 450,000 shares. Credit Suisse Ag accumulated 96,247 shares. Advisory Serv Ntwk Ltd Liability accumulated 6,500 shares or 0% of the stock. Pura Vida Invs Lc invested in 0.39% or 150,000 shares. Parametric Associates Llc accumulated 0% or 11,072 shares. The Ontario – Canada-based Manufacturers Life Insurance The has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Rock Springs Mgmt Limited Partnership owns 450,000 shares or 0.11% of their US portfolio. Moreover, State Street has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 2.97M shares. Aqr Capital Limited Liability has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Baker Bros Advisors Limited Partnership holds 14.00M shares. Group One Trading Lp holds 0% or 47,367 shares in its portfolio.

Since September 18, 2017, it had 0 insider purchases, and 1 insider sale for $294,035 activity.

Nathan Fischel increased its stake in Biocryst Pharmaceuticals Inc (BCRX) by 101.86% based on its latest 2017Q3 regulatory filing with the SEC. Dafna Capital Management Llc bought 602,100 shares as the company’s stock declined 16.46% while stock markets rallied. The hedge fund run by Nathan Fischel held 1.19 million shares of the health care company at the end of 2017Q3, valued at $6.25 million, up from 591,128 at the end of the previous reported quarter. Dafna Capital Management Llc who had been investing in Biocryst Pharmaceuticals Inc for a number of months, seems to be bullish on the $529.57 million market cap company. The stock increased 0.94% or $0.05 during the last trading session, reaching $5.38. About 436,916 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since March 14, 2017 and is uptrending. It has outperformed by 58.38% the S&P500.

Dafna Capital Management Llc, which manages about $196.24 million and $161.05 million US Long portfolio, decreased its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 41,500 shares to 262,121 shares, valued at $24.15M in 2017Q3, according to the filing.

More important recent BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news were published by: which released: “Biocryst Pharmaceuticals Inc (BCRX) Files 10-K for the Fiscal Year Ended on …” on March 12, 2018, also published article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 2017 Results …”, published: “BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming …” on February 19, 2018. More interesting news about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was released by: and their article: “BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy …” with publication date: February 27, 2018.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 14 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. BioCryst Pharmaceuticals had 34 analyst reports since August 7, 2015 according to SRatingsIntel. JP Morgan downgraded it to “Neutral” rating and $5 target in Tuesday, February 9 report. The firm has “Buy” rating given on Wednesday, November 8 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, September 6 by Jefferies. The firm earned “Market Perform” rating on Thursday, August 4 by JMP Securities. The firm has “Neutral” rating by Bank of America given on Friday, October 9. The firm has “Overweight” rating given on Friday, August 12 by PiperJaffray. The firm has “Buy” rating by Jefferies given on Tuesday, February 9. Ladenburg Thalmann initiated the shares of BCRX in report on Thursday, February 16 with “Buy” rating. As per Tuesday, January 23, the company rating was maintained by H.C. Wainwright. On Tuesday, February 9 the stock rating was downgraded by Needham to “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: